$IOVA 2Q2026 ER (Cont.)
Updated my DCF valuation model after the earnings report. Main changes:
1. Increased the assumed U.S. 2L+ melanoma ramp, including higher 2026 and 2027 full-year revenue estimates. This is supported by the stronger-than-expected Q2 Amtagvi revenue, with